Published Date: 02 Mar 2023
It has been three weeks since Tugce Seren Gul's aunt and grandmother died in Antakya during the massive earthquake that hit southern Turkey.
Read Full NewsA meta-analysis identifies impaired effort-based decision making across psychiatric disorders, pointing to actionable targets for improving motivation and functional outcomes.
Comments on a Medscape feature push past ideology to ask what evidence, oversight, and safeguards should be available for patients who choose assisted death.
Patients aged 70 years or older stand to benefit from adjuvant chemotherapy for triple-negative breast cancer, but the majority do not receive it.
Researchers conducted a systematic review and meta-analysis for studies of acute myeloid leukemia patients with a median age less than 70 treated with HMA plus venetoclax.
Nearly 400 trials and Belgium’s isotope hub signal rapid clinical diversification for radioligand therapy — but policy, funding, and system readiness must follow.
1.
A US health panel advises starting mammograms at age 40 rather than 50.
2.
Morning Immunotherapy Does Not Boost Lung Cancer Survival
3.
New protocols, according to a study, allow many patients to safely return home one day after lung cancer surgery.
4.
Antitumor mRNA-based vaccines show potential against gastric cancer metastasis
5.
Cardiopulmonary fitness is key for helping breast cancer patients manage post-diagnosis symptoms, say researchers
1.
Optimizing Platelet Transfusions: Balancing Benefits and Risks in Modern Hematology
2.
The Algorithmic Revolution: How AI is Reshaping Precision Oncology from Bench to Bedside
3.
Navigating the Stages of Thyroid Cancer: A Guide for Patients
4.
Personalized Cancer Vaccines: The Next Frontier in Precision Oncology
5.
Vaso Occlusive Crisis: Understanding the Painful Reality of Sickle Cell Disease
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Navigating the Complexities of Ph Negative ALL - Part XIV
2.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part IV
3.
Cost Burden/ Burden of Hospitalization For R/R ALL Patients
4.
Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Conclusion
5.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part VI
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation